Health Care · Pharmaceutical Preparations

ARDX ARDELYX, INC. SEC Filings & Insider Trading Activity 2026

company
CIK 1437402130 filings
Russell 2000

ARDX at a glance

ARDELYX, INC. (ARDX, SEC CIK 1437402) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), ARDELYX, INC. (ARDX) reported revenue of $407.3 million (up 22.1% from FY2024) and a net loss of $61.6 million. Diluted EPS was -$0.26.
  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding ARDELYX, INC. (ARDX) shares worth $335.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Reilly Joseph James on August 21, 2026 of 2,872 shares at $3.86 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$407.3M
+22.1% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
28 funds
$335.6M · −2 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02 · Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Development and commercialization of innovative medicines focused on tenapanor-based therapies for gastrointestinal and kidney diseases
  • New emphasis on Phase 3 trial initiation in January 2026 for tenapanor in chronic idiopathic constipation (CIC), targeting a new patient population of 34 million Americans
  • Strategic shift: Navigating the 2025 Medicare Part D reimbursement change eliminating coverage for XPHOZAH, focusing on preserving patient access despite revenue impact
  • Notable quantitative metric: Cash, cash equivalents, and short-term investments increased 5.8% to $264.7 million as of December 31, 2025, supporting ongoing operations and growth
  • Significant IP advancement: Receipt of U.S. Patent No. 12,539,299 in January 2026 extending protection for tenapanor formulations in IBSRELA and XPHOZAH until 2042

Risk Factors

  • Regulatory risk: CMS inclusion of XPHOZAH in ESRD PPS on Jan 1, 2025, eliminated Medicare Part D coverage, materially reducing 2025 XPHOZAH revenue
  • Geopolitical/macro risk: Foreign price controls in Europe, Canada, Japan, China may limit IBSRELA and XPHOZAH pricing and reduce international revenue
  • Operational risk: Dependence on third-party CMOs for manufacturing IBSRELA and XPHOZAH with single-source suppliers risks supply interruptions and regulatory non-compliance
  • Competitive risk: Market acceptance and payer coverage pressures for IBSRELA and XPHOZAH amid existing and developing alternative therapies
  • Financial risk: Accumulated deficit of $946.9M as of Dec 31, 2025, with continued losses risking cash flow sustainability and reliance on future fundraising

Management Discussion & Analysis

  • Total revenue $407.3M, up 22% YoY from $333.6M in 2024; product sales $377.8M, up 18% YoY from $319.2M
  • Operating expenses $448.3M, up 24% YoY from $361.6M; cost of sales down 22% to $39.5M vs $50.6M; R&D up 37% to $71.5M; SG&A up 30% to $337.2M
  • Best performing segment: IBSRELA sales $274.2M, up 73% YoY; worst: XPHOZAH sales $103.6M, down 36% YoY due to Medicare Part D reimbursement loss
  • Cash, cash equivalents, and short-term investments $264.7M vs. $250.1M in 2024; no shares sold under ATM offerings in 2025; debt financing amended with $50M drawn in June 2025 plus $100M available through 2026
  • Management outlook: ongoing Phase 3 trial for CIC indication with topline data in H2 2027; advancing next-generation NHE3 inhibitor program; key risk in payor mix and reimbursement changes impacting sales and GTN adjustments (30.2% in 2025 vs 25.6% prior year)

AI summary of the ARDX 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $127.655M vs $110.329M, up $17.326M YoY
  • GTN adjustment rate 31.7% vs 30.6%; unfavorable channel mix and higher rebate charges
  • Best performer IBSRELA sales $96.286M vs $78.158M; XPHOZAH sales $29.169M vs $27.357M
  • Liquid funds $285.338M vs $264.689M; Term F Loan added $50.0M
  • Operating cash use $36.465M, down from $63.434M; outlook funds operations at least one year

Risk Factors

  • New regulatory risk: March 27, 2026 CMS guidance expects ESRD facilities to furnish XPHOZAH under bundled payment
  • Most material update: June 26, 2026 appellate dismissal upheld XPHOZAH’s ESRD PPS challenge
  • Operational risk: Three manufacturing stages rely on single-source CMOs with no qualified alternatives
  • Financial risk: $200.0 million outstanding principal under SLR term loans as of September 30, 2026
  • Competitive risk: At least four phosphate binders remain in development, including two Phase 3 programs

AI summary of the ARDX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Ardelyx announced financial results for the quarter ended September 30, 2026
  • Full quarterly results and management commentary are provided in Exhibit 99.1

Item 7.01: Regulation FD Disclosure

  • Earnings presentation for quarter ended September 30, 2026 furnished as Exhibit 99.2
  • November 3, 2026 conference call covering quarterly financial results

Item EX-99.1: Item EX-99.1

  • Q3 product revenue $125.5M, up 19%, led by IBSRELA revenue $96.3M, up 23%
  • XPHOZAH revenue $29.2M, up 7%, indicating slower growth than IBSRELA

Item EX-99.2: Item EX-99.2

  • Q3 product revenue $125.5M, up 19% YoY, with IBSRELA growth offsetting slower XPHOZAH expansion
  • IBSRELA revenue $96.3M, up 23% YoY, supporting long-term $1B annual revenue ambition
Filed Aug 17, 2026Full analysis →

Item 8.01: Other Events

  • Chief Commercial Officer Eric Foster resigning effective August 28, 2026
  • Departure for a new opportunity at a pre-commercial company
Filed Aug 6, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Ardelyx announced financial results for Q2 2026, the quarter ended June 30, 2026
  • Full results and management commentary are provided in Exhibit 99.1, the key document for investor review

Item 7.01: Regulation FD Disclosure

  • Earnings presentation scheduled for August 6, 2026 conference call
  • Presentation covers financial results for quarter ended June 30, 2026

Item EX-99.2: Item EX-99.2

  • Q2 product revenue $118.1M, up 31% YoY, the company’s largest revenue quarter
  • IBSRELA revenue $86.2M, up 33% YoY, but FY2026 guidance reduced to $350M-$370M from $410M-$430M

Item EX-99.1: Item EX-99.1

  • Q2 product revenue $118.1M, up 31% YoY, with IBSRELA $86.2M and XPHOZAH $31.9M
  • IBSRELA guidance cut to $350–$370M as payor utilization management pressures near-term growth

AI summaries of ARDX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ARDX

Don't miss the next ARDX filing

  • Alerts as it files. A push when ARDX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ARDX, by share count.
  • Ask anything. An AI agent that reads every ARDX filing and answers with sources.

ARDX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
RAAB MICHAELFNov 19, 2026$3.06
Hohenleitner SusanFNov 19, 2026$3.06
Reilly Joseph JamesFNov 19, 2026$3.06
Bishop John EFNov 19, 2026$3.06
Kelliher MikeFNov 19, 2026$3.06
Brady James ParkerFNov 19, 2026$3.06
Reilly Joseph JamesSellAug 21, 2026$3.86
Hohenleitner SusanSellAug 21, 2026$3.86

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$333.6M$407.3M
Operating Income-$63.3M-$27.9M-$41.0M
Net Income-$66.1M-$39.1M-$61.6M
Op. Margin--8.4%-10.1%
Net Margin--11.7%-15.1%
Balance Sheet
Total Assets$297.6M$435.8M$501.6M
Equity-$173.3M$166.9M
ROE--22.6%-36.9%
Per Share
EPS$-0.30$-0.17$-0.26
Cash Flow
Operating CF--$44.8M-$42.5M
CapEx-$1.0M$1.5M

Source: XBRL data in ARDELYX, INC. (ARDX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ARDX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ARDX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$335.6M
Q2 202630$477.1M
Q1 202629$560.6M
Q4 202525$508.6M
Q3 202527$526.2M
Q2 202526$336.4M
Q1 202525$266.5M
Q4 202418$198.4M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 208 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ARDX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 20, 2026--
10-QNov 3, 2026Analysis
8-KNov 3, 2026Analysis-
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
4Aug 25, 2026--
8-KAug 17, 2026Analysis-
SC 13GAug 14, 2026-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jul 17, 2026--
8-KJul 2, 2026Analysis-
4Jun 22, 2026--
4Jun 18, 2026--
4Jun 18, 2026--

Related Health Care companies

All Health Care →

ARDX SEC filings: frequently asked questions

Which institutions hold ARDX stock?

As of September 30, 2026, the largest ARDELYX, INC. (ARDX) holders among the 13F filers tracked by SignalX were BlackRock ($97.0 million), Millennium Management ($46.0 million), State Street Corp ($45.3 million), Vanguard Capital Management LLC ($35.7 million), Vanguard Portfolio Management LLC ($27.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ARDX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), ARDELYX, INC. (ARDX) reported revenue of $407.3 million (up 22.1% from FY2024) and a net loss of $61.6 million. Diluted EPS was -$0.26. The figures come from the XBRL data in the 10-K.

What are the main risks in ARDX's latest 10-K?

In the 10-K filed February 19, 2026, ARDELYX, INC. (ARDX) flagged: Regulatory risk: CMS inclusion of XPHOZAH in ESRD PPS on Jan 1, 2025, eliminated Medicare Part D coverage, materially reducing 2025 XPHOZAH revenue. Geopolitical/macro risk: Foreign price controls in Europe, Canada, Japan, China may limit IBSRELA and XPHOZAH pricing and reduce international revenue. (AI summary of the Risk Factors section.)

What did ARDX report in its latest 8-K?

ARDELYX, INC. (ARDX) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Ardelyx announced financial results for the quarter ended September 30, 2026.

What are the latest ARDX SEC filings?

ARDELYX, INC. (ARDX) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on November 20, 2026.

What is ARDX's SEC CIK number?

ARDELYX, INC. (ARDX)'s SEC Central Index Key (CIK) is 1437402. EDGAR lists every ARDX filing under that number.

Ask anything about ARDX

The research agent reads ARDX's filings, financials, insider trades and 13F holders, then answers with sources.